Biofrontera AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BFFTF research report →
About the company
Biofrontera AG operates as a biopharmaceutical enterprise, dedicated to the exploration, evolution, and commercialization of dermatological therapies. Its flagship offerings, Ameluz and the BF-RhodoLED lamp, are utilized for treating mild to moderate actinic keratoses on the face and scalp, managing field cancerization, and addressing life-threatening squamous cell carcinoma. The company is also advancing RhodoLED XL, intended for extensive interspersed lesions, and provides Belixos, an innovative cosmetic product designed for sensitive and irritated skin.
- CEO
- Pilar de la Huerta Martinez
- IPO
- 2018
- Employees
- 97
- HQ
- Leverkusen, DE
Price Chart
- Market Cap
- $19.35M
- P/E
- -1.06
- P/S
- 0.30
- P/B
- 1.94
- EV/EBITDA
- -1.43
- Div Yield
- 0.00%
- Gross Margin
- 82.79%
- Op Margin
- -20.64%
- Net Margin
- -25.66%
- ROE
- -476.72%
- ROIC
- -62.07%
- Revenue
- $34.07M · 18.82%
- Net Income
- $-20,131,000 · -3045.47%
- EPS
- $-13.02 · -2034.43%
- Op Income
- $-22,677,000
- FCF YoY
- -53.35%
- 52W High
- $22.68
- 52W Low
- $0.33
- 50D MA
- $22.68
- 200D MA
- $22.68
- Beta
- 0.59
- Avg Volume
- 0
Get TickerSpark's AI analysis on BFFTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BFFTF coverage
Recent articles, reports, and earnings notes.
No research on BFFTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BFFTF report →Similar companies
Peers in the same neighborhood.